Evaluating Treatment as Prevention Among People Who Inject Drugs in Dundee for HCV (ERAPID HCV)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03356405|
Recruitment Status : Not yet recruiting
First Posted : November 29, 2017
Last Update Posted : March 20, 2018
|Condition or disease|
|Hepatitis C Viral|
Show Detailed Description
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||2800 participants|
|Target Follow-Up Duration:||6 Years|
|Official Title:||Evaluating Treatment as Prevention Among People Who Inject Drugs in Dundee for HCV|
|Estimated Study Start Date :||April 1, 2018|
|Estimated Primary Completion Date :||December 31, 2023|
|Estimated Study Completion Date :||December 31, 2023|
- The number of HCV positive tests recorded in NHS Tayside. [ Time Frame: 6 years ]The number of reactive DBST conducted in NHS Tayside.
- The number of patients engaged in treatment and SVR12 during the treatment phase [ Time Frame: 6 years ]The numbers of patients who are treated for HCV and the number who achieve an SVR12.
- The cost of treatment [ Time Frame: 6 years ]The cost of treating HCV infection in PWID will be measured.
- Re-infection with HCV following treatment [ Time Frame: 6 years ]Annual routine offer of HCV testing
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03356405
|Contact: Sarah Inglis, PhD||01382 email@example.com|
|Contact: John Dillon, MD||01382 firstname.lastname@example.org|
|Dundee, United Kingdom, DD1 9SY|